-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TST-003 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TST-003 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TST-003 in Solid Tumor Drug Details: TST-003 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TST-003 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TST-003 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TST-003 in Metastatic Colorectal Cancer Drug Details: TST-003 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Osemitamab in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Osemitamab in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Osemitamab in Metastatic Biliary Tract Cancer Drug Details: Osemitamab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Osemitamab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Osemitamab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Osemitamab in Pancreatic Ductal Adenocarcinoma Drug Details: Osemitamab (TST-001) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Osemitamab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Osemitamab in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Osemitamab in Gastric Cancer Drug Details: Osemitamab (TST-001) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axitinib SR in Non-Proliferative Diabetic Retinopathy (NPDR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axitinib SR in Non-Proliferative Diabetic Retinopathy (NPDR) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axitinib SR in Non-Proliferative Diabetic Retinopathy (NPDR) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SynKIR-110 in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SynKIR-110 in Malignant Pleural Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SynKIR-110 in Malignant Pleural Mesothelioma Drug Details: SynKIR-110 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zilovertamab Vedotin in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Chordoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Chordoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Chordoma Drug Details: Tazemetostat hydrobromide (Tazverik) is an anti-neoplastic...